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Standard outcomes for gestational diabetes 
 
















Outcomes in gestational diabetes Cochrane protocols and reviews before and after development 
of ‘standard outcomes’ by WOMBAT (WOMen and Babies health and wellbeing: Action through 
Trials) were surveyed. An increase in ‘common’ outcomes (those pre-specified by ≥ 50% of the 
protocols and reviews) over time was observed (2001-09: 27 vs. 2010-14: 46). There were 
discrepancies in outcomes pre-specified in reviews and reported by randomised trials. Efforts are 




Gestational diabetes mellitus (GDM), traditionally defined as any degree of glucose intolerance 
with onset or first recognition during pregnancy,1 is one of the most common medical 
complications of pregnancy. The estimated global prevalence of hyperglycaemia in pregnancy 
(including GDM, and ‘total diabetes’ (known/unknown pre-existing diabetes)) is 16.9%;2 recent 
Australian GDM prevalence estimates range from 9.6% to 16.0% depending on diagnostic criteria 
used.3,4 
 
In the short-term, mothers with GDM have higher risks of pre-eclampsia and preterm birth; their 
infants may be born large-for-gestational age, and are more likely to be born by caesarean 
section, or face complications, including shoulder dystocia during vaginal birth.5 Predisposition to 
type 2 diabetes, obesity and cardiovascular disease are potential, serious, long-term 
consequences.5 Despite controversy surrounding the diagnosis of GDM, including at what degree 
of hyperglycaemia interventions should be initiated, there is good evidence that risks of many 




With the recognition of an increasing prevalence of GDM worldwide, and its serious short- and 
long-term consequences for the mother and child, there has been an explosion of randomised 
trials and systematic reviews focused on interventions for prevention, detection, management and 
follow up. Acknowledging that waste in research may result from important outcomes not being 
assessed (or reported) in trials and reviews,7,8 in Australia, the WOMBAT (WOMen and Babies 
health and wellbeing: Action through Trials) Collaboration recognised a need to standardise 
outcomes.9 WOMBAT was funded by a National Health and Medical Research Council (NHMRC) 
enabling grant (2005-2010) to support high-quality randomised trials in the perinatal area. In 
2009, lists of ‘standard outcomes’, including for GDM, were developed through extraction (from 
selected trials and reviews) and group harmonisation, and published on the Collaboration’s 
website.9 Recently, the COMET (Core Outcome Measures in Effectiveness Trials) Initiative was 
established specifically to assist the development and application of ‘core outcome sets’ (COS): 
“the minimum that should be measured and reported in all clinical trials of a specific condition.”10 
There is currently no COS for GDM research. 
 
The aim of this study was to survey outcomes used in GDM Cochrane protocols and reviews 
before and after the development ‘standard outcomes’ by WOMBAT (2009), as one approach by 




The Cochrane Library was searched using the term “gestational diabetes” (in Title, Abstract, and 
Keywords) on 19 March 2014. We included Cochrane reviews and protocols (documents 
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describing rationale, objectives and methods for reviews1) addressing interventions for 
prevention, detection, management or follow-up of GDM. 
 
Data collected included: date published; information regarding methods (scope; number and 
choices of pre-specified primary and secondary outcomes); and results (number of included 
randomised trials (and dates published), and number of included trials reporting data for pre-
specified review outcomes). Primary outcomes in Cochrane reviews are those “that would be 
expected to be analysed... and conclusions... based largely on”;11 while secondary outcomes are 
those “used to evaluate additional effects of the intervention deemed a priori as being less 
important than the primary outcomes.”11 
 
Data analysis involved simple number, mean and percentage description, and results are 
presented narratively (and using a table and figure), comparing outcomes in Cochrane protocols 




Cochrane protocol and review characteristics 
 
We included four protocols and 13 reviews, with six (one protocol, five reviews) published before 
(2001-2009), and 11 (three protocols, eight reviews) after (2010-2014) WOMBAT’s ‘standard 
outcomes.’ The scope of the protocols and reviews included GDM prevention (5, 29%), detection 
(2, 12%), management (8, 47%) and follow up (2, 12%). The number of included randomised 
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trials in the 13 reviews was 49 (mean: 4 trials per review). Dates of publications of the included 
trials ranged from 1983 to 2012. 
 
Cochrane primary and secondary outcomes 
 
Protocols and reviews before and after WOMBAT’s ‘standard outcomes’ were consistent in 
number of pre-specified primary outcomes (mean: 4) and choices. There were a total of 12 
different pre-specified primary maternal outcomes (most commonly: GDM and caesarean birth), 
and nine different pre-specified primary child outcomes (most commonly perinatal mortality, large-
for-gestational age and macrosomia).  
 
An increase in the number of pre-specified secondary outcomes after WOMBAT’s ‘standard 
outcomes’ was observed (mean: 26 in 2001-2009 vs. 48 in 2010-2014), particularly an increase in 
pre-specification of longer-term outcomes for the mother and her child (mean: 1 in 2001-2009 vs. 
19 in 2010-2014). Accordingly, the total number of pre-specified outcomes increased over time 
(Figure 1). 
 
Cochrane ‘common’ outcomes 
 
An increase in the number of ‘common’ pre-specified outcomes (defined as outcomes pre-
specified by ≥ 50% of all protocols/reviews), relating to the mother, her child, and the use of 
health services was observed after WOMBAT’s ‘standard outcomes’ (27 in 2001-2009 vs. 46 in 





Outcome data from included randomised trials 
 
For primary outcomes in Cochrane reviews, less than half of the included randomised trials 
reported data at all, or in a way that could be included in a meta-analysis. Considering the most 
common primary outcomes in reviews, the percentages of included trials reporting data were: 
GDM: 47% (8/17 trials; four reviews); caesarean: 40% (16/40 trials; nine reviews); perinatal 
mortality: 23% (6/26 trials; six reviews); large-for gestational age: 30% (9/30 trials; six reviews); 
macrosomia: 37% (11/30 trials; six reviews). Included randomised trials did not report outcome 




‘Core outcomes’ for GDM randomised trials and systematic reviews have the potential to increase 
value and reduce research waste.10 COS are designed to be the minimum that all trials or 
reviews in a particular area collect; thus making it easier for results to be compared and 
combined, such as in reviews.10 
 
We surveyed outcomes in Cochrane protocols and reviews before and after the development of 
GDM ‘standard outcomes’ by WOMBAT (as one approach by which to assess progress towards a 
COS for GDM), and observed increases in the total number of pre-specified outcomes, and in the 
number of ‘common’ outcomes in Cochrane reviews over time. It is possible that some of this 
change may be attributed to the WOMBAT Initiative. However we acknowledge that increased 
recognition and understanding of the widespread consequences of GDM (particularly the longer-
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term effects for the mother and child) also likely contributed to the progress towards standardised 
outcomes that we observed. We noted discrepancies between the outcomes pre-specified by 
Cochrane reviews, and reported by randomised trials, with less than half of the included trials 
reporting relevant data. This may reflect that the outcome data were not collected in the trials 
(with some measuring intermediate outcomes only, and many reporting no longer-term follow), or 
the selective reporting of outcome data by trials, for example, with a lack of reporting due to no 
observed statistical significance, or journal publication space restrictions.8 However, this could 
reflect a ‘lag’ time between recognition by trialists of the importance of some outcomes (such as 
longer-term maternal and child outcomes), and the subsequent collection and reporting of 
relevant outcome data. 
 
To date, additional published efforts focused on standardising outcomes for GDM research are 
limited to one other study in the United States.12 In a research priority setting initiative, ‘high 
priority’ maternal and child outcomes relating to medication and birth management for women 
with GDM were identified, defined as those appearing in the top three lists of two or more of nine 
national stakeholders.12 The ‘priority’ outcomes identified by this study were shared by the list of 
‘common’ Cochrane protocol and review outcomes we identified, and similarly included longer-
term outcomes for the mother and child.  
 
There is now a need to move further towards an international COS for GDM research, guided by 
COMET and associated initiatives, including CROWN (CoRe Outcomes in WomeN’s health).13 
Proposed methods for developing COS include a systematic literature review to identify outcomes 
that have been previously reported, a Delphi study using these outcomes in a number of rounds, 
and a final consensus meeting with all relevant stakeholders to review the outcomes.14 
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Encouragingly, one project, aiming to develop a COS for trials in screening, prevention and 
treatment of GDM has been proposed.15 
 
There will be challenges for developing core outcomes for GDM research; a recent systematic 
review identified that of 198 studies involving development of COS, only 1% (2) were in the 
pregnancy and childbirth field,14 demonstrating the lack of experience in this area to date. The 
pre-specified outcomes in Cochrane GDM protocols and reviews are many (compared with in 
other health care areas16); prioritisation of a ‘core set’ will need to involve and balance carefully 
the views of relevant stakeholders.14 Harmonising definitions for outcomes in a GDM COS may 
be difficult. Whether one set that spans GDM prevention to follow up should be developed or 
separate sets, such as for prevention, detection, management and follow up, is unclear. Despite 
these challenges, core outcomes for GDM research, building on the work described here, have 
potential to reduce research waste, and ultimately contribute to preventing and reducing the 
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Figure 1: Number of pre-specified outcomes in GDM Cochrane protocols and reviews, and, 
where applicable, number of outcomes with no data from included trials (2001-2014, N=17) 






Table 1: Common pre-specified outcomes in Cochrane GDM protocols and reviews (2001-2014, 
N=17) 
 
Protocol or review outcomes 
Mother Child Health services 
Perinatal Fetal/neonatal Hospital or health 
professional visits for the 
mother 
GDM* Perinatal mortality Length of postnatal stay 
(mother) 
Pre-eclampsia Large-for-gestational age Admission to neonatal ward 
Weight gain during 
pregnancy* 
Macrosomia Length of postnatal stay 
(baby) 
Use of insulin or other 
hypoglycaemic agent 
Birthweight Costs of maternal care 
Induction of labour Small-for-gestational age* Costs of offspring care* 
Caesarean section Ponderal index*  
Perineal trauma Gestational age at birth  
Postpartum haemorrhage Preterm birth  
Postpartum infection Shoulder dystocia  
Sense of wellbeing and 
quality of life 
Bone fracture  
View of the intervention Nerve palsy  
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Longer-term Respiratory distress 
syndrome 
 
BMI* Apgar score (less than seven 
at five minutes)* 
 





Type 2 diabetes* Hyperbilirubinaemia requiring 
treatment 
 
Type 1 diabetes* Childhood  
Impaired glucose tolerance* BMI*  
 Fat mass/fat-free mass*  
 Skinfold thickness 
measurements* 
 
 Blood pressure*  
 Type 2 diabetes*  
 Type 1 diabetes*  
 Impaired glucose tolerance*  
 Dyslipidaemia or metabolic 
syndrome* 
 
 Neurodisability*  
 





Abbreviations: BMI: body mass index; GDM: gestational diabetes mellitus 
 
 
